We have some exciting news to share! The Motley Fool UK has now become The Twelfth Magpie -- an independent, UK-owned company, led by our long-serving UK management team — Mark Rogers, Chris Nials and Heather Adlington. In practical terms, it’s the same team you know, now fully focused on serving our UK readers and members.

Just as importantly, our approach remains unchanged: long-term, jargon-free, and on your side. This site is our new home, and there will be extra tweaks made across the coming few days as we settle in. So if anything looks a little off, please bear with us!

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Is the S&P 500 heading for a stock market crash?

The S&P 500’s surged by double digits yet again in 2025, but can this momentum continue in 2026, or are US stocks about to come crashing down?

| More on:
Tabletop model of a bear sat on desk in front of monitors showing stock charts

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Twelfth Magpie’s Premium Investing Services. Become a member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more, and get a free 'Best Buy Now' stock!.

In 2025, the S&P 500‘s gone from strength to strength. Supported by the stellar performance of tech giants, America’s flagship index has climbed another 14.5% since January, or 15.9% when counting dividends.

But after generating a 26.3% gain in 2023, followed by a 26.9% boost in 2024, is the market momentum slowing? And could 2026 see yet another stock market correction, or even full blown crash?

Should you buy Cellebrite shares today?

Before you decide, please take a moment to review this report first. Despite ongoing uncertainties from US tariffs to global conflicts, Mark Rogers and his team believe many UK shares still trade at substantial discounts, offering savvy investors plenty of potential opportunities to learn about.

That’s why this could be an ideal time to secure this valuable research – Mark’s analysts have scoured the markets to reveal 5 of his favourite long-term ‘Buys’. Please, don’t make any big decisions before seeing them.

Three warning signs vs three bull signs

According to institutional analysts, there are a variety of forces at work that could indeed trigger a market downturn. But three of the most prominent include:

  1. Extreme market concentration – 34.4% of the entire S&P 500 is concentrated into just the Magnificent Seven stocks, with almost half of all earnings driven by a handful of tech giants.
  2. A fragile labour market – US unemployment’s steadily creeping upwards, reaching a new four-year high of 4.6% in November, hiking the risk of a looming recession.
  3. Elevated valuations – lofty share prices relative to earnings, particularly within sectors like artificial intelligence (AI), are raising the risk of volatility.

With these factors in mind, it isn’t so surprising to see some investors grow nervous. However, despite the rising pessimism, a crash or even a correction is by no means guaranteed. In fact, there are several reasons why the S&P 500 could continue to outperform next year:

  1. Massive economic stimulus – new corporate and consumer tax cuts in 2026 are estimated to contribute $285bn of stimulus (roughly 1% of US GDP).
  2. More interest rate cuts – continued downward adjustments to interest rates by the Federal Reserve could offset recession risks and stimulate stock prices higher.
  3. AI productivity gains – tangible benefits of using AI tools are starting to emerge, with profit margins as a whole slowly starting to expand.

What now?

My strategy hasn’t changed. I’m avoiding popular overvalued stocks and focusing on finding under-the-radar opportunities. And one that I’ve recently added to my ISA is Cellebrite (NASDAQ:CLBT).

As a quick introduction, Cellebrite’s the world leader in mobile phone decryption technology. Its tools are used by almost all law enforcement agencies across the US and Europe for criminal and cybersecurity investigations. And 2026 could be a transformational year. Let me explain.

In 2024, management began the process of securing FedRAMP authorisation – a certification that allows Cellebrite to offer its cloud services to US federal agencies that have exceptionally rigorous security clearance requirements.

It’s not an easy certification to acquire, and there have been multiple delays. However, Cellebrite appears to be on track to finally receive the greenlight early next year. And current estimates suggest it could add anywhere between $50m and $150m to the group’s annual recurring revenue.

Considering total revenue in 2024 was $401m, that’s a massive growth catalyst potentially just around the corner.

Of course, it does introduce some significant risks. Federal customers already make up around 20% of the company’s revenue stream. And with FedRAMP, this concentration would likely increase even further, making Cellebrite vulnerable to future government spending cuts.

That’s a risk investors will need to consider carefully. But personally, given the near-term and long-term growth opportunities, it’s one I’ve decided to take with a small opening position of 2% of my growth portfolio. But it’s not the only US stock I’ve been snapping up.

Zaven Boyrazian has positions in Cellebrite. The Motley Fool UK has recommended Cellebrite. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

A row of satellite radars at night
Investing Articles

This ex-penny stock has crushed Rolls-Royce shares over 5 years! Is there more to come?

With all eyes on Rolls-Royce shares, this growth share with a connection to SpaceX might have gone unnoticed by a…

Read more »

Close-up as a woman counts out modern British banknotes.
Investing Articles

With a 6.4% yield and P/E of 10 is this FTSE dividend stock a hidden passive income gem?

Building a portfolio of solid UK dividend stocks isn't hard. Paul Summers takes a closer look at one high-yielding candidate…

Read more »

Black woman using smartphone at home, watching stock charts.
Growth Shares

At 112p, where next for the Lloyds share price? 168p or 56p?

Jon Smith mulls over the direction going forward for the Lloyds share price, and explains why two very different scenarios…

Read more »

Investing Articles

This dividend stock has a 7.3% yield, and Stocks and Shares ISA investors are buying!

Looking to move from a Cash ISA to a Stocks and Shares ISA to target passive income? Alan Oscroft has…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

Could Rolls-Royce shares lock in another 34% gain before Christmas?

Mark Hartley takes a look at some of the more optimistic price targets for Rolls-Royce, and considers a best-case scenario.…

Read more »

This way, That way, The other way - pointing in different directions
Investing Articles

Investec vs Aberdeen: which is the better income stock to buy?

Aiming to boost the average yield of his income portfolio, Mark Hartley's looking for new income stocks to buy on…

Read more »

Asian man looking concerned while studying paperwork at his desk in an office
Investing Articles

Down 41% since January, this quality S&P 500 stock is stinking out my ISA

The tide's turned against this S&P 500 robotics stock. Is it time to dump it? Or is there a no-brainer…

Read more »

GSK scientist holding lab syringe
Investing Articles

By mid-2027, analysts expect £6,000 in GSK shares to be worth…

GSK shares are currently trading almost 20% below their 2026 highs. Is there potential for a rebound over the next…

Read more »